As previously mentioned, positive immunoselection-based techniques directly capture CTCs from a blood sample by using the capture antibodies that specifically target tumor-associated antigens (e.g., EpCAM and CK) expressed on the surface of CTCs [105]. The gene discussed is EPCAM; the disease is neoplasm.